Who
Giuseppe Ciaramella
President
Company insider
Files Form 4 as: President, Beam Therapeutics.
In numbers
- Trades disclosed
- 127
- Buys
- 0
- Sells
- 18
- Bought
- $0
- Sold
- $30.0M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 5 Feb 2020
- Last trade
- 24 Sep 2026
- Last filed
- 25 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Sep 2026filed 25 Sep 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code G | —123,407 at $0.00 | filing |
| 24 Sep 2026filed 25 Sep 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code G | —123,407 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code M | $4,3586,505 at $0.67 | filing |
| 17 Jun 2026filed 22 Jun 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code M | $30K29,000 at $1.03 | filing |
| 17 Jun 2026filed 22 Jun 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —6,505 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —6,505 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —29,000 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —29,000 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code M | $4,3586,505 at $0.67 | filing |
| 17 Jun 2026filed 22 Jun 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code M | $30K29,000 at $1.03 | filing |
| 1 Apr 2026filed 6 Apr 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $290K11,810 at $24.58 | filing |
| 1 Apr 2026filed 6 Apr 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $290K11,810 at $24.58 | filing |
| 31 Mar 2026filed 2 Apr 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code M | $595K35,000 at $17.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $1.1M35,000 at $32.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —35,000 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code M | —35,000 at $0.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Code M | $595K35,000 at $17.00 | filing |
| 24 Feb 2026filed 26 Feb 2026 | BEAM Beam TherapeuticsGenomics & Gene Editing | SEC FORM 4 Sold | $1.1M35,000 at $32.00 | filing |
News
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?BEAM · fool.com · 18 Oct 2026Beam Therapeutics (NASDAQ: BEAM) CEO sells 50,000 shares after option exerciseBEAM · tickerreport.com · 17 Oct 2026Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual CongressBEAM · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Giuseppe Ciaramella; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.